Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Hypoxia-mediated impaired erythrocyte Lands' Cycle is pathogenic for sickle cell disease.

Wu H, Bogdanov M, Zhang Y, Sun K, Zhao S, Song A, Luo R, Parchim NF, Liu H, Huang A, Adebiyi MG, Jin J, Alexander DC, Milburn MV, Idowu M, Juneja HS, Kellems RE, Dowhan W, Xia Y.

Sci Rep. 2016 Jul 20;6:29637. doi: 10.1038/srep29637.

2.

Erratum to: Untargeted metabolomic analysis for the clinical screening of inborn errors of metabolism.

Miller MJ, Kennedy AD, Eckhart AD, Burrage LC, Wulff JE, Miller LAD, Milburn MV, Ryals JA, Beaudet AL, Sun Q, Sutton VR, Elsea SH.

J Inherit Metab Dis. 2016 Sep;39(5):757. doi: 10.1007/s10545-016-9944-y. No abstract available.

3.

Plasma metabolomic profiles enhance precision medicine for volunteers of normal health.

Guo L, Milburn MV, Ryals JA, Lonergan SC, Mitchell MW, Wulff JE, Alexander DC, Evans AM, Bridgewater B, Miller L, Gonzalez-Garay ML, Caskey CT.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):E4901-10. doi: 10.1073/pnas.1508425112. Epub 2015 Aug 17.

4.

Untargeted metabolomic analysis for the clinical screening of inborn errors of metabolism.

Miller MJ, Kennedy AD, Eckhart AD, Burrage LC, Wulff JE, Miller LA, Milburn MV, Ryals JA, Beaudet AL, Sun Q, Sutton VR, Elsea SH.

J Inherit Metab Dis. 2015 Nov;38(6):1029-39. doi: 10.1007/s10545-015-9843-7. Epub 2015 Apr 15. Erratum in: J Inherit Metab Dis. 2016 Sep;39(5):757.

5.

Bladder cancer biomarker discovery using global metabolomic profiling of urine.

Wittmann BM, Stirdivant SM, Mitchell MW, Wulff JE, McDunn JE, Li Z, Dennis-Barrie A, Neri BP, Milburn MV, Lotan Y, Wolfert RL.

PLoS One. 2014 Dec 26;9(12):e115870. doi: 10.1371/journal.pone.0115870. eCollection 2014.

6.

Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics.

Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, Jaffa M, Milburn MV, Ryals JA, Bowser R, Cudkowicz ME, Berry JD; Northeast ALS Consortium.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):362-70. doi: 10.3109/21678421.2014.908311. Epub 2014 Jul 1.

PMID:
24984169
7.

Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression.

Zhang Y, Berka V, Song A, Sun K, Wang W, Zhang W, Ning C, Li C, Zhang Q, Bogdanov M, Alexander DC, Milburn MV, Ahmed MH, Lin H, Idowu M, Zhang J, Kato GJ, Abdulmalik OY, Zhang W, Dowhan W, Kellems RE, Zhang P, Jin J, Safo M, Tsai AL, Juneja HS, Xia Y.

J Clin Invest. 2014 Jun;124(6):2750-61. doi: 10.1172/JCI74604. Epub 2014 May 16.

8.

An atlas of genetic influences on human blood metabolites.

Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, Arnold M, Erte I, Forgetta V, Yang TP, Walter K, Menni C, Chen L, Vasquez L, Valdes AM, Hyde CL, Wang V, Ziemek D, Roberts P, Xi L, Grundberg E; Multiple Tissue Human Expression Resource (MuTHER) Consortium, Waldenberger M, Richards JB, Mohney RP, Milburn MV, John SL, Trimmer J, Theis FJ, Overington JP, Suhre K, Brosnan MJ, Gieger C, Kastenmüller G, Spector TD, Soranzo N.

Nat Genet. 2014 Jun;46(6):543-550. doi: 10.1038/ng.2982. Epub 2014 May 11.

9.

Serum metabolomics indicate altered cellular energy metabolism in children with cystic fibrosis.

Joseloff E, Sha W, Bell SC, Wetmore DR, Lawton KA, Milburn MV, Ryals JA, Guo L, Muhlebach MS.

Pediatr Pulmonol. 2014 May;49(5):463-72. doi: 10.1002/ppul.22859. Epub 2013 Jul 12.

PMID:
23847148
10.

Metabolomic signatures of aggressive prostate cancer.

McDunn JE, Li Z, Adam KP, Neri BP, Wolfert RL, Milburn MV, Lotan Y, Wheeler TM.

Prostate. 2013 Oct;73(14):1547-60. doi: 10.1002/pros.22704. Epub 2013 Jul 3.

11.

Metabolomic signatures in lipid-loaded HepaRGs reveal pathways involved in steatotic progression.

Brown MV, Compton SA, Milburn MV, Lawton KA, Cheatham B.

Obesity (Silver Spring). 2013 Dec;21(12):E561-70. doi: 10.1002/oby.20440. Epub 2013 Jun 13.

12.

Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats.

Yamazaki M, Miyake M, Sato H, Masutomi N, Tsutsui N, Adam KP, Alexander DC, Lawton KA, Milburn MV, Ryals JA, Wulff JE, Guo L.

Toxicol Appl Pharmacol. 2013 Apr 1;268(1):79-89. doi: 10.1016/j.taap.2013.01.018. Epub 2013 Jan 27.

PMID:
23360887
13.

Application of metabolomics to diagnosis of insulin resistance.

Milburn MV, Lawton KA.

Annu Rev Med. 2013;64:291-305. doi: 10.1146/annurev-med-061511-134747. Review.

PMID:
23327524
14.

Metabolomic profiles in individuals with negative affectivity and social inhibition: a population-based study of Type D personality.

Altmaier E, Emeny RT, Krumsiek J, Lacruz ME, Lukaschek K, Häfner S, Kastenmüller G, Römisch-Margl W, Prehn C, Mohney RP, Evans AM, Milburn MV, Illig T, Adamski J, Theis F, Suhre K, Ladwig KH.

Psychoneuroendocrinology. 2013 Aug;38(8):1299-309. doi: 10.1016/j.psyneuen.2012.11.014. Epub 2012 Dec 10.

PMID:
23237813
15.

Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance.

Ferrannini E, Natali A, Camastra S, Nannipieri M, Mari A, Adam KP, Milburn MV, Kastenmüller G, Adamski J, Tuomi T, Lyssenko V, Groop L, Gall WE.

Diabetes. 2013 May;62(5):1730-7. doi: 10.2337/db12-0707. Epub 2012 Nov 16.

16.

Research Highlights: Highlights from the latest articles in metabolomic studies of cancer.

Milburn MV.

Per Med. 2012 Nov;9(8):793-794. doi: 10.2217/pme.12.93. No abstract available.

PMID:
29776227
17.

Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information.

Krumsiek J, Suhre K, Evans AM, Mitchell MW, Mohney RP, Milburn MV, Wägele B, Römisch-Margl W, Illig T, Adamski J, Gieger C, Theis FJ, Kastenmüller G.

PLoS Genet. 2012;8(10):e1003005. doi: 10.1371/journal.pgen.1003005. Epub 2012 Oct 18.

18.

Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies.

Brown MV, McDunn JE, Gunst PR, Smith EM, Milburn MV, Troyer DA, Lawton KA.

Genome Med. 2012 Apr 30;4(4):33.

19.

Biochemical alterations associated with ALS.

Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, Bowser R, Lawson R, Jaffa M, Milburn MV, Ryals JA, Berry JD.

Amyotroph Lateral Scler. 2012 Jan;13(1):110-8. doi: 10.3109/17482968.2011.619197. Epub 2011 Nov 25.

PMID:
22117131
20.

Human metabolic individuality in biomedical and pharmaceutical research.

Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wägele B, Altmaier E; CARDIoGRAM, Deloukas P, Erdmann J, Grundberg E, Hammond CJ, de Angelis MH, Kastenmüller G, Köttgen A, Kronenberg F, Mangino M, Meisinger C, Meitinger T, Mewes HW, Milburn MV, Prehn C, Raffler J, Ried JS, Römisch-Margl W, Samani NJ, Small KS, Wichmann HE, Zhai G, Illig T, Spector TD, Adamski J, Soranzo N, Gieger C.

Nature. 2011 Aug 31;477(7362):54-60. doi: 10.1038/nature10354.

21.

Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists.

Zgoda-Pols JR, Chowdhury S, Wirth M, Milburn MV, Alexander DC, Alton KB.

Toxicol Appl Pharmacol. 2011 Aug 15;255(1):48-56. doi: 10.1016/j.taap.2011.05.015. Epub 2011 May 27.

PMID:
21640743
22.

Detrimental effects of adenosine signaling in sickle cell disease.

Zhang Y, Dai Y, Wen J, Zhang W, Grenz A, Sun H, Tao L, Lu G, Alexander DC, Milburn MV, Carter-Dawson L, Lewis DE, Zhang W, Eltzschig HK, Kellems RE, Blackburn MR, Juneja HS, Xia Y.

Nat Med. 2011 Jan;17(1):79-86. doi: 10.1038/nm.2280. Epub 2010 Dec 19.

23.

Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting.

Suhre K, Meisinger C, Döring A, Altmaier E, Belcredi P, Gieger C, Chang D, Milburn MV, Gall WE, Weinberger KM, Mewes HW, Hrabé de Angelis M, Wichmann HE, Kronenberg F, Adamski J, Illig T.

PLoS One. 2010 Nov 11;5(11):e13953. doi: 10.1371/journal.pone.0013953.

24.

Metabolomic profiling reveals biochemical pathways and biomarkers associated with pathogenesis in cystic fibrosis cells.

Wetmore DR, Joseloff E, Pilewski J, Lee DP, Lawton KA, Mitchell MW, Milburn MV, Ryals JA, Guo L.

J Biol Chem. 2010 Oct 1;285(40):30516-22. doi: 10.1074/jbc.M110.140806. Epub 2010 Jul 30.

25.

Ethylene glycol monomethyl ether-induced toxicity is mediated through the inhibition of flavoprotein dehydrogenase enzyme family.

Takei M, Ando Y, Saitoh W, Tanimoto T, Kiyosawa N, Manabe S, Sanbuissho A, Okazaki O, Iwabuchi H, Yamoto T, Adam KP, Weiel JE, Ryals JA, Milburn MV, Guo L.

Toxicol Sci. 2010 Dec;118(2):643-52. doi: 10.1093/toxsci/kfq211. Epub 2010 Jul 8.

26.

alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population.

Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ, Ryals JA, Milburn MV, Nannipieri M, Camastra S, Natali A, Ferrannini E; RISC Study Group.

PLoS One. 2010 May 28;5(5):e10883. doi: 10.1371/journal.pone.0010883.

27.

Assessment of the effects of dentifrice on periodontal disease biomarkers in gingival crevicular fluid.

Barnes VM, Teles R, Trivedi HM, Devizio W, Xu T, Lee DP, Mitchell MW, Wulff JE, Milburn MV, Guo L.

J Periodontol. 2010 Sep;81(9):1273-9. doi: 10.1902/jop.2010.100070.

PMID:
20450373
28.

Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline.

Sha W, da Costa KA, Fischer LM, Milburn MV, Lawton KA, Berger A, Jia W, Zeisel SH.

FASEB J. 2010 Aug;24(8):2962-75. doi: 10.1096/fj.09-154054. Epub 2010 Apr 6.

29.

Acceleration of purine degradation by periodontal diseases.

Barnes VM, Teles R, Trivedi HM, Devizio W, Xu T, Mitchell MW, Milburn MV, Guo L.

J Dent Res. 2009 Sep;88(9):851-5. doi: 10.1177/0022034509341967.

PMID:
19767584
30.

Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats.

Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, Ryals JA, Beebe KD, Guo L.

Toxicol Pathol. 2009 Jun;37(4):521-35. doi: 10.1177/0192623309336152.

PMID:
19458390
31.

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.

Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, Habets G, West BL, Zhang KY, Milburn MV, Vlasuk GP, Hirth KP, Nolop K, Bollag G, Ibrahim PN, Tobin JF.

Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. doi: 10.1073/pnas.0811325106. Epub 2008 Dec 30.

32.

Analysis of the adult human plasma metabolome.

Lawton KA, Berger A, Mitchell M, Milgram KE, Evans AM, Guo L, Hanson RW, Kalhan SC, Ryals JA, Milburn MV.

Pharmacogenomics. 2008 Apr;9(4):383-97. doi: 10.2217/14622416.9.4.383.

PMID:
18384253
33.

The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1.

Wang W, Zhang C, Marimuthu A, Krupka HI, Tabrizizad M, Shelloe R, Mehra U, Eng K, Nguyen H, Settachatgul C, Powell B, Milburn MV, West BL.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7505-10. Epub 2005 May 16.

34.

A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.

Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY.

Nat Biotechnol. 2005 Feb;23(2):201-7. Epub 2005 Jan 30.

35.

Structural basis for the activity of drugs that inhibit phosphodiesterases.

Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY.

Structure. 2004 Dec;12(12):2233-47.

36.

A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.

Zhang KY, Card GL, Suzuki Y, Artis DR, Fong D, Gillette S, Hsieh D, Neiman J, West BL, Zhang C, Milburn MV, Kim SH, Schlessinger J, Bollag G.

Mol Cell. 2004 Jul 23;15(2):279-86. Erratum in: Mol Cell. 2004 Aug 27;15(4):659.

37.

Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix.

Gampe RT Jr, Montana VG, Lambert MH, Wisely GB, Milburn MV, Xu HE.

Genes Dev. 2000 Sep 1;14(17):2229-41.

38.

Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.

Gampe RT Jr, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, Xu HE.

Mol Cell. 2000 Mar;5(3):545-55.

39.

Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity.

Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, Nolte RT.

Science. 2000 Jun 9;288(5472):1822-5.

40.

Crystallization of native and selenomethionyl yeast orotidine 5'-phosphate decarboxylase.

Miller BG, Hassell AM, Milburn MV, Short SA.

Acta Crystallogr D Biol Crystallogr. 2000 Apr;56(Pt 4):472-4.

PMID:
10739924
41.
42.

Molecular determinants of nuclear receptor-corepressor interaction.

Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, Rose DW, Lambert MH, Milburn MV, Glass CK, Rosenfeld MG.

Genes Dev. 1999 Dec 15;13(24):3198-208.

43.

The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways.

Kliewer SA, Lehmann JM, Milburn MV, Willson TM.

Recent Prog Horm Res. 1999;54:345-67; discussion 367-8. Review.

PMID:
10548883
44.

A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation.

Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, Plunket K, Miller AB, Milburn MV, Kliewer SA, Willson TM.

Proc Natl Acad Sci U S A. 1999 May 25;96(11):6102-6.

45.

Molecular recognition of fatty acids by peroxisome proliferator-activated receptors.

Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV.

Mol Cell. 1999 Mar;3(3):397-403.

46.

Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation.

McInerney EM, Rose DW, Flynn SE, Westin S, Mullen TM, Krones A, Inostroza J, Torchia J, Nolte RT, Assa-Munt N, Milburn MV, Glass CK, Rosenfeld MG.

Genes Dev. 1998 Nov 1;12(21):3357-68.

47.

Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators.

Westin S, Kurokawa R, Nolte RT, Wisely GB, McInerney EM, Rose DW, Milburn MV, Rosenfeld MG, Glass CK.

Nature. 1998 Sep 10;395(6698):199-202.

PMID:
9744281
48.

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma.

Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV.

Nature. 1998 Sep 10;395(6698):137-43.

PMID:
9744270
49.

The three-dimensional structure of human interleukin-5 at 2.4-angstroms resolution: implication for the structures of other cytokines.

Wells TN, Graber P, Proudfoot AE, Arod CY, Jordan SR, Lambert MH, Hassel AM, Milburn MV.

Ann N Y Acad Sci. 1994 May 28;725:118-27. No abstract available.

PMID:
8030983
50.

Preliminary X-ray diffraction studies of recombinant 19 kDa human fibroblast collagenase.

Hassell AM, Anderegg RJ, Weigl D, Milburn MV, Burkhart W, Smith GF, Graber P, Wells TN, Luther MA, Jordan SR.

J Mol Biol. 1994 Mar 11;236(5):1410-2.

PMID:
8126730

Supplemental Content

Loading ...
Support Center